ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: L4 • 2014 ACR/ARHP Annual Meeting

    Safety and Efficacy of Sifalimumab, an Anti IFN-Alpha Monoclonal Antibody, in a Phase 2b Study of Moderate to Severe Systemic Lupus Erythematosus (SLE)

    Munther Khamashta1,2, Joan T. Merrill3, Victoria P. Werth4,5, Richard Furie6, Kenneth Kalunian7, Gabor G. Illei8, Jorn Drappa8, Liangwei Wang8 and Warren Greth8, 1Division of Women's Health, Graham Hughes Lupus Research Laboratory, King's College London, London, United Kingdom, 2Lambeth Wing, The Rayne Institute, St Thomas' Hospital London, London, United Kingdom, 3Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Philadelphia VA Medical Center, Philadelphia, PA, 5University of Pennsylvania, Philadelphia, PA, 6North Shore-LIJ Health System, Lake Success, NY, 7UCSD School of Medicine, La Jolla, CA, 8MedImmune, LLC, Gaithersburg, MD

    Background/Purpose: Efficacy and safety of sifalimumab were assessed in a Phase 2b, randomized, double-blind, placebo (PBO)-controlled study in subjects with SLE (NCT01283139). Methods: Adults (n=431)…
  • Abstract Number: L2 • 2014 ACR/ARHP Annual Meeting

    A Comparison of Three Treatment Strategies in Recent Onset DMARD Naïve Juvenile Idiopathic Arthritis: 3-Months Results of the BeSt for Kids-Study

    Petra C.E. Hissink Muller1,2, D.M.C. Brinkman1,3, Dieneke Schonenberg4, Yvonne Koopman-Keemink5, J. Merlijn Van den Berg6, W.P. Bekkering7, Marion van Rossum8,9, Lisette WA van Suijlekom-Smit10, Cornelia F. Allaart11 and Rebecca ten Cate1, 1Pediatric Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 2Pediatric Rheumatology, Reade, Amsterdam, Netherlands, 3Pediatric Rheumatology, Rijnland Hospital, Leiderdorp, Netherlands, 4Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 5Pediatrics, Haga ziekenhuis, The Hague, Netherlands, 6Pediatric Hematology, Immunology and Infectious diseases, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 7Pediatric Physiotherapy, Leiden University Medical Center, Leiden, Netherlands, 8Pediatric Rheumatology Immunology, Emma Children's Hospital, Academic Medical Center, Amsterdam, Netherlands, 9Reade, Amsterdam, Netherlands, 10Pediatric Rheumatology, Sophia Children's Hospital Erasmus Medical Center, Rotterdam, Netherlands, 11Rheumatology, Leiden University Medical Center, Leiden, Netherlands

    Background/Purpose: BeSt for Kids compares 3 Disease Modifying Anti Rheumatic Drug (DMARD) strategies in juvenile idiopathic arthritis (JIA) patients, for time to inactive disease, time…
  • Abstract Number: L13 • 2014 ACR/ARHP Annual Meeting

    Monthly Ibandronate Reduces Bone Loss in Osteopenic Women with Rheumatoid Arthritis Receiving Long-Term Glucocorticoids: A 48-Week Double-Blinded Randomized Placebo-Controlled Investigator-Initiated Trial

    Kichul Shin1, Sung-Hwan Park2, Won Park3, Han Joo Baek4, Yun Jong Lee5, Seong-Wook Kang6, Jung-Yoon Choe7, Wan-Hee Yoo8, Yong-Beom Park9, Jung-Soo Song10, Bin Yoo11, Dae-Hyun Yoo12 and Yeong Wook Song13, 1Rheumatology, SMG-SNU Boramae Medical Center, Seoul, South Korea, 2Division of Rheumatology, Department of Internal Medicine, Seoul St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea, 3Medicine/Rheumatology, Inha University Hospital, Incheon, South Korea, 4Division of Rheumatology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, South Korea, 5Division of Rheumatology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea, 6Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, South Korea, 7Division of Rheumatology, Catholic University of Daegu School of Medicine, Daegu, South Korea, 8Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, 9Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea, 10Rheumatology, Chung-Ang Univ Hospital, Seoul, South Korea, 11Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea, 12Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 13Department of Molecular Medicine and Biopharmaceutical Sciences, BK 21 plus Graduate School of Convergence Science and Technology, and College of Medicine, Seoul National University, Seoul, South Korea

    Background/Purpose: Long-term use of glucocorticoids (GC) is problematic for patients with increased risk for vertebral fractures, especially those with rheumatoid arthritis (RA). Thus, prevention of…
  • Abstract Number: L11 • 2014 ACR/ARHP Annual Meeting

    Raman Spectroscopy: Point of Service Diagnosis Is Sensitive and Specific-a Tool for Improving Accuracy and Reducing Future Hospital Admission

    Nora Singer1, Bolan Li2, Yener Yeni3, Emma Barnboym4, Steven Lewis5, Daniel Oravec6, Donald Haggins7 and Ozan Akkus2, 1Rheumatology, MetroHealth Medical Center and CWRU, Cleveland, OH, 2Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, 3Section of Biomechanics, Bone and Joint Cetner, Henry Ford Hospital, Detroit, MI, 4Rheumatology, MetroHealth Medical Center, Cleveland, OH, 5Medicine, MetroHealth Medical Center, Cleveland, OH, 6Bone and Joint Center, Henry Ford Hospital, Detroit, MI, 7Rheumatology, Henry Ford Hospital, Detroit, MI

    Background/Purpose: The diagnosis of gout or pseudogout hinges upon identification of monosodium urate (MSU) crystals and calcium pyrophosphate (CPPD) crystals in synovial fluid (SF) aspirates…
  • Abstract Number: L9 • 2014 ACR/ARHP Annual Meeting

    Contrast Enhanced Ultrasonography in Patients Diagnosed with Early Arthritis: A Preliminary Experience

    Maria-Magdalena Tamas1, Nicolae Rednic2, Ana Petcu1, Cosmina Ioana Bondor3, Horatiu Popoviciu4, Eugenia Mociran5 and Simona Rednic1, 1Department of Rheumatology, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, 24th Medical Clinic Cluj-Napoca, Cluj-Napoca, Romania, 3Department of Medical Informatics and Biostatistics, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania, 4Rheumatology, University of Medicine and Pharmacy Targu Mures, Tg Mures, Romania, 5Rheumatology, Policlinica "Sf. Ioan" Baia Mare, Baia Mare, Romania

    Background/Purpose: The role of ultrasonography (US) in early rheumatoid arthritis (ERA) for detecting synovial hypertrophy and its vascularity has already been demonstrated. Contrast enhanced ultrasonography…
  • Abstract Number: L18 • 2014 ACR/ARHP Annual Meeting

    14-3-3eta Informs Joint Pathological Mechanisms of Treatment Response to Assist with T2T Strategies

    Shintaro Hirata1, Kentaro Hanami2, Anthony Marotta3 and Yoshiya Tanaka4, 1The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 2The first department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 31423 Dempsey Road, Augurex Life Sciences Corp., North Vancouver, BC, Canada, 4University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

    Background/Purpose: A primary clinical goal of RA in treating to target (T2T) is to improve long term outcomes including the control of symptoms and prevention…
  • Abstract Number: L19 • 2014 ACR/ARHP Annual Meeting

    Randomized Trial of Stopping TNF-Inhibitors in Rheumatoid Arthritis Patients with Stable Low Disease Activity in the Netherlands

    Harald E. Vonkeman1, Marjan Ghiti Moghadam2, Mart A.F.J. van De Laar3, Peter M. ten Klooster4, Tim Jansen5 and Piet van Riel6, 1Rheumatology, Medisch Spectrum Twente, Enschede, Netherlands, 2rheumatology, Enschede, Netherlands, 3Rheumatology, Medisch Spectrum Twente & University of Twente, Enschede, Netherlands, 4Psychology, Health & Technology, University of Twente, Enschede, Netherlands, 5Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, 6Rheumatology, Nijmegen, Netherlands

    Background/Purpose: The effectiveness of TNF-inhibitors (TNFi) in the treatment of rheumatoid arthritis has already been demonstrated in many studies. However, little is known on stopping…
  • Abstract Number: L10 • 2014 ACR/ARHP Annual Meeting

    Lesinurad, a Novel Selective Uric Acid Reabsorption Inhibitor, in Two Phase III Clinical Trials: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR 1 and 2)

    Kenneth G. Saag1, Scott Adler2, Nihar Bhakta3, Maple Fung3, Jeff Kopicko3, Chris Storgard3 and Thomas Bardin4, 1Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, 2AstraZeneca Pharmaceuticals, Wilmington, DE, 3Ardea Biosciences, Inc., San Diego, CA, 4Clinique de Rhumatologie. Service de Rhumatologie. Centre Viggo Petersen., Hôpital Lariboisière, Paris, France

    Background/Purpose: Inadequate response to allopurinol monotherapy is common. Lesinurad (RDEA594) is a selective uric acid reabsorption inhibitor (SURI) under investigation for treatment of gout in…
  • Abstract Number: L24 • 2014 ACR/ARHP Annual Meeting

    A Progressive Increase in T Follicular Helper Cells Marks the Transition from Benign to Symptomatic Autoimmunity

    Sina Rusta-Sallehy1, Babak Noamani2, Dennisse Bonilla3, Nan-Hua Chang4, Larissa Lisnevskaia5, Sindhu R. Johnson6, Earl Silverman7, Arthur A. M. Bookman8, Joan E. Wither9 and Carolina Landolt-Marticorena3, 1Medicine, University of Toronto, Toronto, ON, Canada, 2Genetics and developmental biology, Toronto Western Research Institute, Toronto, ON, Canada, 3Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, 4Genetics and Development, Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada, 5Rheumatology, Lakeridge Health Center, Toronto, ON, Canada, 6Medicine, Toronto Scleroderma Program, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada, 7Division of Rheumatology, Hosp for Sick Children, Toronto, ON, Canada, 8Division of Rheumatology, Toronto Western Hospital (UHN), Toronto, ON, Canada, 9Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON, Canada

    Background/Purpose: The systemic autoimmune rheumatic diseases (SARD; Systemic Lupus Erythematosus (SLE), Rheumatoid Arthritis (RA), Sjogren’s Disease (SjD), Systemic Sclerosis (SSc)) are proposed to have a…
  • Abstract Number: L22 • 2014 ACR/ARHP Annual Meeting

    Long-Term (104-Week) Safety and Efficacy of Monotherapy with Apremilast in DMARD-Naïve Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial and Open-Label Extension (PALACE 4)

    Alvin Wells1, Christopher Edwards2, Adewale O. Adebajo3, Alan J. Kivitz4, Paul Bird5, Kamal Shah6, ChiaChi Hu6, Randall M. Stevens6 and Jacob A. Aelion7, 1Rheumatology & Immunotherapy Center, Franklin, WI, 2University Hospital Southampton, Southampton, United Kingdom, 3University of Sheffield, Sheffield, United Kingdom, 4Altoona Center for Clinical Research, Duncansville, PA, 5Combined Rheumatology Practice, Sydney, Australia, 6Celgene Corporation, Warren, NJ, 7West Tennessee Research Institute, Jackson, TN

    Background/Purpose: Apremilast (APR) is an oral phosphodiesterase 4 inhibitor that helps regulate the immune response that causes joint inflammation and other manifestations of psoriatic arthritis…
  • Abstract Number: L3 • 2014 ACR/ARHP Annual Meeting

    Low Protein A20 Expression in Minor Salivary Glands Is Associated with Lymphoma Development in Primary Sjögren’s Syndrome

    Svein Joar A. Johnsen1, Einar Gudlaugsson2, Ivar Skaland2, Emiel Janssen2, Malin V. Jonsson3, Lars Helgeland4, Ellen Berget5, Roland Jonsson6 and Roald Omdal1, 1Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 2Stavanger University Hospital, Stavanger, Norway, 3Department of Clinical Dentistry - Section for Oral and Maxillofacial Radiology, University of Bergen, Bergen, Norway, 4Haukeland University Hospital, Bergen, Norway, 5University of Bergen, Bergen, Norway, 6Broegelmann Research Laboratory, Department of Clinical Science, University of Bergen, Bergen, Norway

    Background/Purpose: Patients with primary Sjogrens syndrome (pSS) have an increased risk of developing lymphomas, especially of the subtype mucosa-associated lymphoid tissue (MALT) lymphoma. Chronic antigen…
  • Abstract Number: L15 • 2014 ACR/ARHP Annual Meeting

    Remission Induction By Etanercept in Enthesitis Related Arthritis JIA-Patients (juvenile undifferentiated Spondylarthropathy)

    Ivan Foeldvari1, Gerd Horneff2, Kirsten Minden3, Ralf Trauzeddel4, J B. Kuemmerle-Deschner5, Klaus Tenbrock6, Gerd Ganser7 and Hans-Iko Huppertz8, 1Department of Pediatric Rheumatology, Hamburger Zentrum für Kinder und Jugendrheumatologie, Hamburg, Germany, 2Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 3Chidlrens´ hospital, Charité University Medicine, Berlin, Germany, 4Pediatrics, Helios Clinics, Berlin, Germany, 5Division of Pediatric Rheumatology, Department of Pediatrics, University Hospital Tuebingen, Tuebingen, Germany, 6University Aachen, Aachen, Germany, 7Pediatric Rheumatology, Sankt Josef Stift, Sendenhorst, Germany, 8Kinderklinik, Krinikum Bremen-Mitte, Bremen, Germany

    Background/Purpose: Enthesitis related arthritis (ERA) is a Juvenile Idiopathic Arthritis category, clinically related to the syndrome of undifferentiated spondyloarthropathy in adults. This study is intended…
  • Abstract Number: L23 • 2014 ACR/ARHP Annual Meeting

    Humoral Immune Response to Pneumococcal Polysaccharide Vaccine in SLE Patients on Immunosuppressive Therapy: Assessment of Serotypes without Protective Antibody Levels

    Rodrigo Poubel V. Rezende1, Francinne M. Ribeiro1, Luis Eduardo C. Andrade2, Carlos Roberto M. Gayer3, Elisa M. N. Albuquerque1 and Evandro Mendes Klumb1, 1Rheumatology, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 2Fleury Laboratories, Sao Paulo, Brazil, 3Department of Biochemistry, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil

    Background/Purpose: Previous works assessing antibody response to pneumococcal polysaccharide vaccine (PPV) in systemic lupus erythematosus (SLE) relied exclusively on the quantitative increase in antibody titers…
  • Abstract Number: 197 • 2013 ACR/ARHP Annual Meeting

    Discordance Of Patient-Physician Assessments Of General Health In a US Hispanic Population With Rheumatoid Arthritis

    Leyda Díaz-Correa1, Mariely Nieves-Plaza2, Yesenia C. Santiago-Casas3, Tania González-Rivera4, Grissel Ríos3 and Luis M. Vilá3, 1Department of Medicine, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 2University of Pittsburgh, Pittsburgh, PA, 3Department of Medicine, Division of Rheumatology, University of Puerto Rico Medical Sciences Campus, San Juan, PR, 4Department of Medicine, Division of Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI

    Background/Purpose: Instruments to measure rheumatoid arthritis (RA) activity such as the 28-Joint Disease Activity Score (DAS28) are used to assess response to treatment. One component…
  • Abstract Number: 198 • 2013 ACR/ARHP Annual Meeting

    Accuracy Of International Classification Of Diseases (Ninth Revision) Coding For Rheumatoid Arthritis In The Primary Care Setting

    Sheena Ogando1, Karolina M. Weiss1 and Harry D. Fischer2, 1Department of Medicine, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY, 2Division of Rheumatology, Albert Einstein College of Medicine at Beth Israel Medical Center, New York, NY

    Background/Purpose: Current quality measures are diagnosis driven and focus on management.  For rheumatoid arthritis (RA), the Physician Quality Reporting System requires that a disease modifying…
  • « Previous Page
  • 1
  • …
  • 2232
  • 2233
  • 2234
  • 2235
  • 2236
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology